RxDoctor Payments Data

Nicholas Shuler, DO

Hematology & Oncology · Kansas City, MONPI 1790103513

Payments from drug & device makers

$17,529in general payments, 2019–2025

Across 750 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Merck$2K
  • Johnson & Johnson$1K
  • Novartis$1K
  • Gilead$941
  • GSK$719
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$2021%
  • Food & beverage$16,40394%
  • Education$9245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)77$1,833
Merck73$1,607
Johnson & Johnson54$1,348
Novartis64$1,117
Gilead(2 entities)45$941
GSK30$719
E.r. Squibb & Sons, L.L.C.26$621
Bristol Myers Squibb22$612
Pfizer39$539
Incyte Corporation19$502
Seagen Inc.12$484
Genentech USA, Inc.15$464
Foundation Medicine, Inc.4$409
Amgen19$388
Regeneron Healthcare Solutions, Inc.15$362
Sanofi17$350
Eisai Inc.20$350
AbbVie15$342
Sanofi-aventis U.S. LLC3$275
Histosonics, Inc.1$222
Pharmacyclics LLC, An Abbvie Company9$217
Lilly USA, LLC7$210
Array Biopharma Inc14$204
Tersera Therapeutics LLC6$175
Daiichi Sankyo Inc.8$175
Bayer8$174
Ipsen Biopharmaceuticals, Inc8$163
Dova Pharmaceuticals3$162
Caris MPI, Inc.1$161
Epizyme, Inc.9$158
Taiho Oncology, Inc.8$157
Exelixis Inc.5$156
AVEO Pharmaceuticals, Inc.7$154
Kyowa Kirin, Inc.8$154
Boehringer Ingelheim7$149
Janssen Scientific Affairs, LLC2$144
Takeda Pharmaceuticals U.S.A., Inc.6$138
Sobi, Inc4$83
AMAG Pharmaceuticals, Inc.6$82
Astellas Pharma US Inc4$70
Rigel Pharmaceuticals, Inc.3$65
Legend Biotech USA Inc.3$61
Puma Biotechnology, Inc.4$58
Global Blood Therapeutics, Inc.2$46
Stemline Therapeutics Inc.3$45
Coherus Oncology, Inc.2$45
Recordati_rare_diseases_inc.2$44
Blueprint Medicines Corporation3$43
Karyopharm Therapeutics Inc.2$41
Sumitomo Pharma America, Inc.2$39
Deciphera Pharmaceuticals Inc.2$39
G1 Therapeutics, Inc.2$39
Myovant Sciences Inc.2$38
Tolmar, Inc.2$37
Myriad Genetic Laboratories, Inc.1$36
Clovis Oncology, Inc.2$35
Boston Scientific2$35
Agios Pharmaceuticals, Inc.1$28
Pharmaessentia USA Corporation1$27
Beigene USA, Inc.2$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,529 in reported general payments places this provider in the 65th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$90,326
Medicare patients
378
Services billed
976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate13$290,981
JakafiRuxolitinib Phosphate13$272,835
RevlimidLenalidomide12$223,396
Lenalidomide17$211,564
ErleadaApalutamide11$161,555
XtandiEnzalutamide13$151,264
VerzenioAbemaciclib12$138,476
EliquisApixaban94$80,749
XareltoRivaroxaban48$42,628
Anastrozole118$2,568
Pregabalin11$1,093
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$975
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen47$807
Oxycodone Hcl29$543
Ondansetron Hcl35$502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$1,833$290,98113 claims
Incyte CorporationJakafi$502$272,83513 claims
Bristol Myers SquibbRevlimid$612$223,39612 claims
Johnson & JohnsonErleada, Xarelto$1,348$204,18359 claims
Astellas Pharma US IncXtandi$70$151,26413 claims
Lilly USA, LLCVerzenio$210$138,47612 claims
PfizerEliquis$539$80,74994 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →